---
title: "Inside Geely’s Ford Partnership, Sunac’s Crisis, and Other Hong Kong Moves"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294039049.md"
description: "Geely is accelerating its European expansion through a joint venture with Ford, while Sunac China's debt crisis continues to hit new lows. We also track Harbour BioMed’s state-backed alliance and Meitu’s AI commercialization efforts. Here is the latest from the Hong Kong market."
datetime: "2026-07-28T09:12:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294039049.md)
  - [en](https://longbridge.com/en/news/294039049.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294039049.md)
generator: "portal-rs"
---

# Inside Geely’s Ford Partnership, Sunac’s Crisis, and Other Hong Kong Moves

The Hong Kong market is telling a tale of two extremes this week. While some ambitious tech and manufacturing giants are aggressively expanding their global footprint, legacy real estate developers are facing an increasingly dire survival test. I am told that Geely’s latest moves in Europe have caught the attention of several Wall Street firms, while the internal situation at Sunac appears more complicated than its balance sheet suggests.

### Geely Auto (0175.HK)

The automaker's recent stock performance has been closely watched, with multiple investment banks raising their target expectations. I’m told that Geely is making a **EUR 221 million** investment to set up a joint venture with Ford in Spain. According to people familiar with the matter, sharing capacity at the Valencia plant is a crucial step to localize new energy vehicle production and bypass potential European trade barriers. The financials back up this confidence, with Q1 2026 sales topping **700,000 units** and revenue seeing double-digit growth.

### Sunac China (1918.HK)

In stark contrast to Geely’s aggressive push is the ongoing decline of Sunac, whose shares recently plunged to an all-time low. Despite completing a massive offshore debt restructuring in 2025, core operating losses remain severe. I'm hearing that another subsidiary recently defaulted on over **RMB 1 billion** in loans. Against the backdrop of a staggering **94.1%** debt-to-asset ratio, the recent grant of incentive shares to hundreds of employees looks more like a desperate attempt to stabilize its core team.

### HBM Holdings (2245.HK)

This biotech player is seeing a major turning point. I'm told the company just inked a strategic partnership with state-owned giant Sinopharm in late July. Industry insiders point out that building a joint innovation consortium provides crucial backing for its long-term oncology and immunology pipeline. The company isn't just surviving; it expects to report its seventh consecutive half-year of profitability, following a massive **314.6%** revenue surge in 2025.

### Meitu (1357.HK)

Meitu is pushing hard to commercialize its AI visual products. According to internal sources, CFO Gary Ngan has been busy setting up offices globally to accelerate international expansion. Based on the latest release of Meitu Yunxiu in late July, the company is pivoting its Agent Teams model from a simple consumer app to a professional B2B productivity tool, attempting to carve out new profit margins in a highly competitive space.

### PCCW (0008.HK)

Hong Kong’s major telecom provider is quietly optimizing its capital structure. I've learned that its wholly-owned subsidiary fully redeemed **USD 750 million** in perpetual subordinated guaranteed securities in mid-July. This move is widely seen as a signal of shoring up financial liquidity ahead of the board’s interim dividend approval expected later this month.

### The Also

-   **CSOP A50 ETF (2840.HK)**: As the broader A-share market fluctuates, fund flows into this large-cap tracking ETF remain a key indicator to watch.
-   **Viva Goods (6088.HK)**: The holding company behind various footwear brands and sports parks is restructuring its sports experience business lines.
-   **361 Degrees (1530.HK)**: The sportswear brand’s penetration strategy in lower-tier markets continues to be tested amid broader consumer spending shifts.
-   **Zhaoke Ophthalmology (2577.HK)**: Commercialization progress in its ophthalmic drug pipeline remains relatively quiet at the moment.
-   **VBG International (2991.HK)**: There is little to no market-moving news or evident catalysts for this financial services firm recently.

*This article does not constitute investment advice.*

### Related Stocks

- [01918.HK](https://longbridge.com/en/quote/01918.HK.md)
- [02245.HK](https://longbridge.com/en/quote/02245.HK.md)
- [01357.HK](https://longbridge.com/en/quote/01357.HK.md)
- [06088.HK](https://longbridge.com/en/quote/06088.HK.md)
- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)
- [02577.HK](https://longbridge.com/en/quote/02577.HK.md)
- [02991.HK](https://longbridge.com/en/quote/02991.HK.md)

## Related News & Research

- [Sunac China Issues 260,258,500 New Shares, Files Next-Day Disclosure With Hong Kong Exchange](https://longbridge.com/en/news/306095172.md)
- [TENG: Record results and digital growth support a £100m net revenue target and 35% margin ambition](https://longbridge.com/en/news/306167367.md)
- [Lygend EGM Approves Seven Resolutions](https://longbridge.com/en/news/305861026.md)
- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)
- [SanRex proposes to acquire Frontage Holdings for HKD 2.370 per share](https://longbridge.com/en/news/304839252.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**